On this page:
The information provided in this Resource Guide was developed by the National Eye Institute (NEI) to help patients and their families search for general information about blepharospasm. An eye care professional who has examined the patient's eyes and is familiar with his or her medical history is the best person to answer specific questions.
Benign essential blepharospasm, hemifacial spasm.
Blepharospasm is an abnormal, involuntary blinking or spasm of the eyelids.
Blepharospasm is associated with an abnormal function of the basal ganglion from an unknown cause. The basal ganglion is the part of the brain responsible for controlling the muscles. In rare cases, heredity may play a role in the development of blepharospasm.
Most people develop blepharospasm without any warning symptoms. It may begin with a gradual increase in blinking or eye irritation. Some people may also experience fatigue, emotional tension, or sensitivity to bright light. As the condition progresses, the symptoms become more frequent, and facial spasms may develop. Blepharospasm may decrease or cease while a person is sleeping or concentrating on a specific task.
To date, there is no successful cure for blepharospasm, although several treatment options can reduce its severity.
In the United States and Canada, the injection of Oculinum (botulinum toxin, or Botox) into the muscles of the eyelids is an approved treatment for blepharospasm. Botulinum toxin, produced by the bacterium Clostridium botulinum, paralyzes the muscles of the eyelids.
Medications taken by mouth for blepharospasm are available but usually produce unpredictable results. Any symptom relief is usually short term and tends to be helpful in only 15 percent of the cases.
Myectomy, a surgical procedure to remove some of the muscles and nerves of the eyelids, is also a possible treatment option. This surgery has improved symptoms in 75 to 85 percent of people with blepharospasm.
Alternative treatments may include biofeedback, acupuncture, hypnosis, chiropractic, and nutritional therapy. The benefits of these alternative therapies have not been proven.
Mexiletine for the Treatment of Focal Dystonia
The National Institute of Neurological Disorders and Stroke (NINDS) is currently recruiting patients to test the effectiveness of mexilitine, an oral medication, to treat Dystonia (involuntary muscle contractions). Patients will be evaluated by clinical rating scales and neurophysiological studies. In addition, researchers will test patient's reflexes in an attempt to find out where mexilitine works in the nervous system. For further information on this study, please visit the NINDS' website at http://www.ninds.nih.gov/disorders/blepharospasm/blepharospasm.htm or contact the NIH Patient Recruitment and Public Liaison Office at 1-800-411-1222.
The Doxil® Blepharospasm Treatment Trial
Doxorubicin injections in the eyelids are being studied as a way of relieving muscle spasms. Patients who participated in this study have experienced symptom relief since their last injection. No definite conclusions have been reached at this time. For additional information about this clinical trial, please visit the University of Minnesota Department of Ophthalmology website at http://www.med.umn.edu/ophthalmology/ or contact:
Jonathan D. Wirtschafter, M.D.
Department of Ophthalmology
University of Minnesota - FUMC Box 493
420 Delaware Street SE
Minneapolis, MN 55455-0501
The following resources may provide additional information on blepharospasm:
American Society of Ophthalmic Plastic and Reconstructive Surgery
1133 West Morse Boulevard #201
Winter Park, FL 32789
Represents ophthalmologists who specialize in reconstructive surgery involving the eye and surrounding structures. Provides information on anophthalmos and orbital implants, blepharospasm, ptosis and other eyelid disorders, excessive tearing, and thyroid disease and the eye.
Benign Essential Blepharospasm Research Foundation
P.O. Box 12468
Beaumont, TX 77726-2468
Distributes informational materials on benign essential blepharospasm. Provides a support system for persons who suffer from the disease. Publishes a bimonthly newsletter. Coordinates a video lending library.
Consensus Development Program
National Institutes of Health
31 Center Drive, MSC 2082
Bethesda, MD 20892-2082
Distributes Clinical Use of Botulinum Toxin Consensus Development Conference Statement, November 12-14, 1990.
For additional information, you may also wish to contact a local library.
Below is a sample of the citations available in MEDLINE, a comprehensive medical literature database coordinated by the National Library of Medicine (NLM). MEDLINE contains information on medical journal articles published from 1966 to the present. You can conduct your own free literature search by accessing MEDLINE through the Internet at http://medlineplus.nlm.nih.gov/. You can also get assistance with a literature search at a local library.
To obtain copies of any of the articles listed below, contact a local community, university, or medical library. If the library you visit does not have a copy of a particular article, you may usually obtain it through an inter-library loan.
Please keep in mind that articles in the medical literature are usually written in technical language. We encourage you to share any articles you order with a health care professional who can help you understand them.
Blepharospasm: Report of a Workshop. Hallett M, Darof, R. Bethesda, Maryland. Neurology; 46(5):1213-1218, May 1996.
This article discusses the anatomy and physiology of the eyelid, clinical aspects of blepharospasm, and treatment options.
Pharmacotherapy with Botulinum Toxin: Harnessing Nature's Most Potent Neurotoxin. Bell MS, Vermeulen LC, Sperling KB. Pharmacotherapy 20(9):1079-91, September 2000.
This article begins with a brief overview of the use of botulinum toxin. Following is a discussion of the past uses of the botulinum toxin and the advances that have been made in its use as a pharmacological treatment for neurological disorders. The article also provides information on the safety and the efficacy of botulinum toxin.
The National Eye Institute (NEI), part of the National Institutes of Health (NIH), is the Federal government's principal agency for conducting and supporting vision research. Inclusion of an item in this Information Resource Guide does not imply the endorsement by the NEI or the NIH.
This page was last modified in December 2006
This information has been provided by The National Eye Institute (NEI)).
Retreived on 8/6/2007